Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate
This article was originally published in PharmAsia News
Executive Summary
Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified
You may also be interested in...
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo